TG THERAPEUTICS, INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
TG THERAPEUTICS, INC. (TGTX) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $2.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-05
- TG THERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $1.23M.
- TG THERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $1.53M.
- TG THERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was -$433.00K.
- TG THERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $420.00K.
- TG THERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was -$298.00K.
- TG THERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$754.00K.
- TG THERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $0.00.
- TG THERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.76M 10-Q · filed 2026-08-05 | $2.33M derived: sum of 3 quarters · filed 2026-08-05 | $2.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.53M 10-Q · filed 2026-05-06 | $1.10M derived: sum of 2 quarters · filed 2026-05-06 | $1.52M derived: sum of 3 quarters · filed 2026-05-06 | $1.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$13.00K derived: sum of 2 quarters · filed 2026-02-27 | -$194.00K derived: sum of 3 quarters · filed 2026-08-05 | -$298.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $420.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $239.00K derived: sum of 2 quarters · filed 2026-08-05 | $135.00K 10-Q · filed 2025-11-05 | -$366.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$181.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$285.00K 10-Q · filed 2026-08-05 | -$786.00K derived: sum of 3 quarters · filed 2026-08-05 | -$861.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$104.00K 10-Q · filed 2026-05-06 | -$605.00K derived: sum of 2 quarters · filed 2026-05-06 | -$680.00K derived: sum of 3 quarters · filed 2026-05-06 | -$1.05M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$501.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$576.00K derived: sum of 2 quarters · filed 2026-02-27 | -$949.00K derived: sum of 3 quarters · filed 2026-02-27 | -$754.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | -$75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$448.00K derived: sum of 2 quarters · filed 2025-11-05 | -$253.00K 10-Q · filed 2025-11-05 | -$253.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$373.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$178.00K 10-Q · filed 2025-08-08 | -$178.00K derived: sum of 3 quarters · filed 2026-02-27 | -$178.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $195.00K 10-Q · filed 2025-05-09 | $195.00K derived: sum of 2 quarters · filed 2026-02-27 | $195.00K derived: sum of 3 quarters · filed 2026-02-27 | $195.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |